影响因子503分的神刊CA-A Cancer Journal for Clinicians是美国癌症协会的旗舰期刊,近日发表综述“Acute myeloid leukemia management and research in 2025”,通讯作者为MD安德森癌症中心Hagop M. Kantarjian教授,作者回顾了AML的一线和后线疗法,...
近日,由高博医学(血液病)广东研究中心南方春富(儿童)血液病研究院作为牵头单位、携手广州市妇女儿童医疗中心团队合作开展的C型凝集素样分子1 (CLL1) CAR-T治疗儿童R/R-AML的Ⅰ/Ⅱ期研究(NCT03222674)中期分析数据全文发表于国际...
此外,靶向CD123、CLL-1、 CLL-1的ADC类药物已被证明具有抗白血病活性。 免疫检查点分子抗AML模式图 参考文献:Tabata, R.; Chi, S.; Yuda, J.; Minami, Y. Emerging Immunotherapy for Acute Myeloid Leukemia. Int. J.Mol. Sci. 2021, 22, 1944. https://doi.org/10.3390/ijms22041944...
维奈托克/维奈克拉(venetoclax)是BCL-2抑制剂,已证明对多种类型的恶性淋巴肿瘤有效,包括复发/难治的CLL缺失17p,总应答率约为80%。维奈克拉(维奈托克)是艾伯维/罗氏联合开发的一款口服B细胞淋巴瘤因子-2(Bcl-2)抑制剂,最早在2016/4/11获得FDA批。 作用机制 BCL-2是一种能抑制细胞(包括癌细胞)凋亡的蛋白,但肿瘤...
而急性髓系白血病(acute myeloid leukemia,AML)是成人中最常见的急性白血病类型,约占成人白血病的70%,并且发病率随年龄增加而增加,确诊时患者中位年龄为68~71岁,超半数的AML患者确诊时的年龄在65岁以上。 因为白血病干细胞(LSC)的持续存在和/或其克隆性演变(“俗称”癌变),50%的AML患者在一线治疗后复发,通常是...
Acute myeloid leukemia (AML) is caused by altered maturation and differentiation of myeloid blasts, as well as transcriptional/epigenetic alterations, all leading to excessive proliferation of malignant blood cells in the bone marrow. Tumor heterogeneity due to the acquisition of new somatic alterations...
急性髓系白血病(Acute myeloid leukemia,AML)是最常见的白血病类型之一,常见于老年人,男性发病率高于女性。AML的特征在于快速增长的异常细胞,积聚在骨髓和血液中,从而干扰正常细胞,常见的临床症状包括感到疲倦、呼吸急促、容易瘀伤和出血以及感染风险增加。AML目前的主要治疗手段包括化疗和造血干细胞移植,如常用的“DA3+7...
et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30, 1044–1054 (2016). CAS PubMed PubMed Central Google Scholar Hochhaus, A. et al. Long-term outcomes of ...
Bimodal Induction of NK Cell Reactivity Against Acute Myeloid (AML) and Chronic Lymphoid Leukemia (CLL) by Fc-Engineered GITR-Fc Fusion Proteins2143 NK cells play an important role in anti-tumor immunity and largely contribute to the efficacy of therapeutic strategies like allogenic stem cell ...
CLL: Chronic lymphocytic leukemia mCR: Bone marrow CR HiDAC: High dose cytarabine (AraC) HMA: Hypomethylating agent LDAC: Low dose cytarabine ITD: Internal tandem duplication TKD: Tyrosine kinase domain ORR: Overall response rate RP2D: Recommended phase 2 dose CLIA: Cladribine, idar...